Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot randomised controlled trial

Rose, M; Holmes, N; Eastwood, G; Vogrin, S; James, F; Phung, M; Barnes, S; Murfin, B; Rogers, B; Lambros, B; Peel, T; Gibney, G; Slavin, M; Trubiano, J

Author(s): Rose, M; Holmes, N; Eastwood, G; Vogrin, S; James, F; Phung, M; Barnes, S; Murfin, B; Rogers, B; Lambros, B; Peel, T; Gibney, G; Slavin, M; Trubiano, J;
Details: Publication Year 2023-07-20,Volume 9,Issue #1,Page 126
Journal Title: Pilot and Feasibility Studies
Publication Type: Research article
Abstract: BACKGROUND: Self-reported penicillin allergies are highly prevalent in hospitalised patients and are associated with poor health and health service outcomes. Critically ill patients have historically been underrepresented in prospective delabelling studies in part due to concerns around clinical stability and reliability of penicillin skin testing. Allergy assessment tools exist to identify low-risk penicillin allergy phenotypes and facilitate direct oral challenge delabelling. PEN-FAST is a clinical decision rule that has been validated to predict true penicillin allergy in a cohort of non-critically ill patients. There is however limited evidence regarding the feasibility, safety and efficacy of direct oral challenges and the use of delabelling clinical decisions rules in the intensive care setting. METHODS: Critically ill patients in the intensive care unit (ICU) with low-risk penicillin allergy phenotypes (PEN-FAST score < 3) will be randomised 1:1 to direct oral penicillin challenge (single dose 250 mg oral amoxicillin or implicated penicillin) or routine care, followed by a 2-h observation period. Patients will receive a second oral challenge/observation prior to hospital discharge (with subsequent observation for 2 h). An assessment for antibiotic-associated adverse events will also be undertaken at 24 h and 5 days post each challenge/observation and again at 90 days post-randomisation. The primary outcome measures are feasibility (proportion of eligible patients recruited and protocol compliance) and safety (proportion of patients who experience an antibiotic-associated immune-mediated adverse event or serious adverse event). DISCUSSION: We will report the feasibility and safety of point-of-care penicillin direct oral challenge in this first randomised controlled trial of low-risk penicillin allergy in critically ill hospitalised patients. Upon completion of the project, important findings will inform the design of planned large prospective multi-centre clinical trials in Australian and international ICUs, further examining safety and efficacy and exploring antimicrobial prescribing-related outcomes following penicillin oral challenge. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Registration Number: ACTRN12621000051842 Date registered: 20/01/2021 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379735&isReview=true.
Publisher: BioMed Central
Keywords: Allergy; Antibiotics; Critical illness; Delabelling; Intensive care; Penicillin
Department(s): Infectious Diseases
PubMed ID: 37475038
Publisher's Version: https://doi.org/10.1186/s40814-023-01337-8
Open Access at Publisher's Site: https://doi.org/10.1186/s40814-023-01337-8
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-10-24 12:20:00

Last Modified: 2023-10-24 12:20:41